MA42036A - Analogues nucléosidiques 5'-substitués - Google Patents

Analogues nucléosidiques 5'-substitués

Info

Publication number
MA42036A
MA42036A MA042036A MA42036A MA42036A MA 42036 A MA42036 A MA 42036A MA 042036 A MA042036 A MA 042036A MA 42036 A MA42036 A MA 42036A MA 42036 A MA42036 A MA 42036A
Authority
MA
Morocco
Prior art keywords
nucleosid
analogues
substitute
substitute nucleosid
nucleosid analogues
Prior art date
Application number
MA042036A
Other languages
English (en)
Inventor
Zahid Quyoom Bonday
Guillermo S Cortez
Karl Robert Dahnke
Michael John Grogan
Antonio Rodriguez HERGUETA
James Andrew Jamison
Brian Morgan Watson
Timothy Andrew Woods
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42036A publication Critical patent/MA42036A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
MA042036A 2015-05-04 2016-04-27 Analogues nucléosidiques 5'-substitués MA42036A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382225 2015-05-04

Publications (1)

Publication Number Publication Date
MA42036A true MA42036A (fr) 2018-03-14

Family

ID=53177322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042036A MA42036A (fr) 2015-05-04 2016-04-27 Analogues nucléosidiques 5'-substitués

Country Status (25)

Country Link
US (1) US9840532B2 (fr)
EP (1) EP3292128A1 (fr)
JP (2) JP6181889B1 (fr)
KR (1) KR20170132871A (fr)
CN (1) CN107580602A (fr)
AR (1) AR104326A1 (fr)
AU (1) AU2016258485A1 (fr)
BR (1) BR112017020336A2 (fr)
CA (1) CA2981097A1 (fr)
CL (1) CL2017002637A1 (fr)
CO (1) CO2017010727A2 (fr)
CR (1) CR20170443A (fr)
DO (1) DOP2017000255A (fr)
EA (1) EA201792169A1 (fr)
EC (1) ECSP17072987A (fr)
HK (1) HK1244007A1 (fr)
IL (1) IL254409A0 (fr)
MA (1) MA42036A (fr)
MX (1) MX2017014001A (fr)
PE (1) PE20180231A1 (fr)
PH (1) PH12017502002A1 (fr)
SG (1) SG11201708345XA (fr)
TN (1) TN2017000459A1 (fr)
TW (1) TWI615400B (fr)
WO (1) WO2016178870A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170384A (es) * 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
WO2018139181A1 (fr) * 2017-01-27 2018-08-02 国立大学法人 宮崎大学 Agent anticancéreux, procédé de criblage pour agent anticancéreux, kit de détermination de l'efficacité sur le cancer et procédé de détermination de l'efficacité sur le cancer
WO2018152501A1 (fr) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
US11220524B2 (en) 2017-02-20 2022-01-11 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2018160855A1 (fr) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
PL3665179T3 (pl) * 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
JP7328218B2 (ja) 2017-10-26 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
PE20211444A1 (es) 2017-12-13 2021-08-05 Lupin Ltd Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CN111971288B (zh) * 2018-03-14 2023-12-01 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
EP3833669A4 (fr) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
BR112021015796A2 (pt) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5)
CN114026094B (zh) 2019-06-10 2024-06-25 印度鲁宾有限公司 Prmt5抑制剂
CN114599361B (zh) 2019-10-22 2024-07-09 印度鲁宾有限公司 Prmt5抑制剂的药物组合物
MX2022006735A (es) 2019-12-03 2022-07-21 Lupin Ltd Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212326A4 (fr) 1999-08-27 2003-08-20 Icn Pharmaceuticals ANALOGUES NUCLEOSIDIQUES DE PYRROLO 2,3-d]PYRIMIDINE
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2011079236A1 (fr) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions et méthodes de détection et de traitement du cancer
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2894126A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CA2894157A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
EP2935242A2 (fr) 2012-12-21 2015-10-28 Epizyme, Inc. Procédés d'inhibition de prmt5
WO2014100716A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
CR20170384A (es) 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos

Also Published As

Publication number Publication date
CL2017002637A1 (es) 2018-04-20
JP6181889B1 (ja) 2017-08-16
CR20170443A (es) 2017-11-07
EA201792169A1 (ru) 2018-03-30
ECSP17072987A (es) 2018-02-28
SG11201708345XA (en) 2017-11-29
US9840532B2 (en) 2017-12-12
EP3292128A1 (fr) 2018-03-14
DOP2017000255A (es) 2018-01-15
PE20180231A1 (es) 2018-01-31
KR20170132871A (ko) 2017-12-04
CA2981097A1 (fr) 2016-11-10
CN107580602A (zh) 2018-01-12
TW201712022A (zh) 2017-04-01
JP2017525667A (ja) 2017-09-07
WO2016178870A1 (fr) 2016-11-10
PH12017502002A1 (en) 2018-03-26
JP2017125029A (ja) 2017-07-20
CO2017010727A2 (es) 2018-01-31
TN2017000459A1 (en) 2019-04-12
TWI615400B (zh) 2018-02-21
BR112017020336A2 (pt) 2019-05-14
MX2017014001A (es) 2018-03-16
IL254409A0 (en) 2017-11-30
HK1244007A1 (zh) 2018-07-27
AR104326A1 (es) 2017-07-12
AU2016258485A1 (en) 2017-10-12
US20160326208A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
MA42036A (fr) Analogues nucléosidiques 5'-substitués
MA46180A (fr) Analogues de l'amyline
DK3490991T3 (da) Coelenterazine analogues
MA45430A (fr) Analogues de célastrol
KR20180084876A (ko) 내플라즈마성 부재
DE112015006486A5 (de) Inkubationsrinne
TR201503831A2 (tr) Antimipertansif kombinasyon formülasyonları
IT201700103032A1 (it) Moschettone
FI11845U1 (fi) Hengityssuoja
FI11901U1 (fi) Paistinlasta
DK3426641T3 (da) Immunoproteasominhibitoranaloger
IT201700090331A1 (it) "lopemide"
UA32431S (uk) Стрем'янка
IT201700071679A1 (it) Remembebe'
ITUB201551290U1 (it) Ovie' oviel
FR3036257B3 (fr) "chaussure"
ITUA20163709A1 (it) "presentosa3d"
FR3041379B1 (fr) Turbopropulseur d'aeronef
UA34360S (uk) Костюм
UA31879S (uk) Стіл-трансформер «маgnат»
UA31878S (uk) Стіл-трансформер «sріdеr»
FR3045273B1 (fr) Piquet d'extremite
FI11130U1 (fi) Kannakerakenne
ES1148074Y (es) Mosqueton autoblocante